SCHEMBL4120225

SCHEMBL4120225

CN1CCN(CCOc2ccc(Br)cc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.69
LTA4H P09960 2/20 0.69
PTGS2 P35354 1/20 0.69
ATM Q13315 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
TSHR P16473 1/20 0.59
KDM4E B2RXH2 2/20 0.58
USP2 O75604 1/20 0.58
ALDH1A1 P00352 1/20 0.58
HPGD P15428 1/20 0.58
RECQL P46063 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
KCNA5 P22460 1/20 0.56
CHIT1 Q13231 1/20 0.56
CHIA Q9BZP6 1/20 0.56
NPC1 O15118 1/20 0.55
HTR1B P28222 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
HRH3 Q9Y5N1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10817906 0.92 RAB9A (0.76) RAB9ALTA4HPTGS2ATML3MBTL1
SCHEMBL27516138 0.87 RAB9A (0.74) RAB9AATML3MBTL1KDM4EUSP2
SCHEMBL7154005 0.86 RAB9A (0.78) RAB9AATML3MBTL1KDM4EUSP2
SCHEMBL229697 0.86 LTA4H (0.90) LTA4HPTGS2ATML3MBTL1TSHR
SCHEMBL10191921 0.84 LTA4H (0.65) RAB9ALTA4HUSP2ALDH1A1HPGD
SCHEMBL227425 0.84 LTA4H (0.87) LTA4HPTGS2ATML3MBTL1KDM4E
SCHEMBL5116881 0.84 LTA4H (0.87) LTA4HPTGS2ATML3MBTL1TSHR
SCHEMBL227976 0.84 LTA4H (0.87) LTA4HPTGS2ATML3MBTL1KDM4E
SCHEMBL6598639 0.84 LTA4H (0.61) RAB9ALTA4HPTGS2ATML3MBTL1
SCHEMBL7954349 0.83 LTA4H (0.63) RAB9ALTA4HKDM4EUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092032-A1 DEOXYCYTIDINE KINASE INHIBITORS INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) 2025-03-20 US disclosed
WO-2020132004-A1 BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD SAINT LOUIS UNIVERSITY (US) 2020-06-25 WO disclosed
US-20090018130-A1 Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid ASTRAZENECA AB (SE) 2009-01-15 US disclosed
EP-1761530-A1 NEW DERIVATIVES OF 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXAMIDE OR 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXYLIC ACID AstraZeneca AB (SE) 2007-03-14 EP disclosed
WO-2006001754-A1 NEW DERIVATIVES OF 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXAMIDE OR 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXYLIC ACID ASTRAZENECA AB (SE) 2006-01-05 WO disclosed
EP-1414801-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 AstraZeneca AB (SE) 2004-05-06 EP disclosed
WO-2003004472-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 ASTRAZENECA AB (SE) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018130-A1 Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid AADAC, PAH, PDE7A RAB9A 524/4885LTA4H 2592/4885PTGS2 2169/4885
US-20250092032-A1 DEOXYCYTIDINE KINASE INHIBITORS DCK, DTYMK, TYMP RAB9A 2529/4885LTA4H 4146/4885PTGS2 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.